Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6

Pharmacogenetics

Volumn 11, Issue 7, 2001, Pages 573-585

  Zanger, U M ^a   Fischer, J ^a   Raimundo, S ^a   Stuven T ^a   Evert, B O ^a   Schwab, M ^a   Eichelbaum, M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Cytochrome P450; Debrisoquine sparteine polymorphism; Intermediate metabolizer; Ultrarapid metabolizer

Indexed keywords

BUFURALOL; CYTOCHROME P450 2D6; DEBRISOQUINE; OXYGENASE; SPARTEINE;

ANIMAL CELL; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER MICROSOME; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT;

CYTOCHROME P-450 CYP2D6; GENE DOSAGE; GENOTYPE; HUMANS; IMMUNOBLOTTING; ISOENZYMES; LIVER; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS;

INSECTA;

EID: 0034790063     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200110000-00004     Document Type: Article

References (43)

1. The cytochrome P450 CYP2D6 allelic variant CYP2D6 J and related polymorphisms in a European population
2. The influence of environmental and genetic factors on CYP2D6. CYP1A2 and UDP-glucuronosyl-transferases in man using sparteine, caffeine, and paracetamol as probes
3. Debrisoquine oxidation polymorphism: Phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene
4. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency
5. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
6. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
7. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
8. Disposition of debrisoquine in Caucasians with different CYP2D6- genotypes including those with multiple genes
9. Nomenclature for human CYP2D6 alleles
10. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects
11. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
12. Cloning and sequencing of a new non-functional CYP2D6 allele: Deletion of T1795 in exon 3 generates a premature stop codon
13. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine
14. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324-Pro) expressed by recombinant baculovirus in insect cells
15. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
16. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
17. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
18. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
19. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase
20. Human cytochrome P450 (CYP) genes: Recommendations for the nomenclature of alleles
21. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
22. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
23. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes
24. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene. A related gene, and a pseudogene
25. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: A system designed for exploring protein-protein interactions
26. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
27. Polymorphic hydroxylation of debrisoquine in man
28. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
29. Molecular mechanisms of genetic polymorphisms of drug metabolism
30. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers
31. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
32. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
33. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype
34. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
35. Molecular genetics of the human cytochrome P450 monooxygenase superfamily
36. Rapid detection of CYP2D6 null alleles by 10ng distance- and multiplex- polymerase chain reaction
37. Interindividual variability in catalytic activity and immuno-reactivity of three major human liver cytochrome P450 isozymes
38. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype
39. The human hepatic cytochromes P450 involved in drug metabolism
40. Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in-vivo rates of sparteine metabolism
41. Immunoisolation of human microsomal cytochromes P450 using autoantibodies
42. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man
43. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II